EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A Gertz iD, Adam D Cohen iD, Raymond L Comenzo iD, Efstathios Kastritis iD, Heather J Landau iD, Edward N Libby, Michaela Liedtke iD, Vaishali Sanchorawala iD, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A Zonder, Giovanni Palladini iD und 7 weitere

Blood · 05.10.2023 · 142 (14) · 1208-1218

DOI: 10.1182/blood.2022019406 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Blood, erschienen am 05.10.2023. Verfasst von Morie A Gertz und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Amyloidosis. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyloid light-chain (AL) amyloidosis is a rare, typically fatal disease characterized by the accumulation of misfolded immunoglobulin light chains (LCs). Birtamimab is an investigational humanized monoclonal antibody designed to neutralize toxic LC aggregates and deplete insoluble organ-deposited amyloid via macrophage-induced phagocytosis. VITAL was a phase 3 randomized, double-blind, placebo-controlled clinical trial assessing the efficacy and safety of birtamimab + standard of care (SOC) in 260 newly diagnosed, treatment-naive patients with AL amyloidosis. Patients received 24 mg/kg IV birtamimab + SOC or placebo + SOC every 28 days. The primary composite end point was the time to all-cause mortality (ACM) or centrally adjudicated cardiac hospitalization ≥91 days after the first study drug infusion. The trial was terminated early after an interim futility analysis; there was no significant difference in the primary composite end point (hazard ratio [HR], 0.826; 95% confidence interval [CI], 0.574-1.189; log-rank P = .303). A post hoc analysis of patients with Mayo stage IV AL amyloidosis, those at the highest risk of early mortality, showed significant improvement in the time to ACM with birtamimab at month 9 (HR, 0.413; 95% CI, 0.191-0.895; log-rank P = .021). At month 9, 74% of patients with Mayo stage IV AL amyloidosis treated with birtamimab and 49% of those given placebo survived. Overall, the rates of treatment-emergent adverse events (TEAEs) and serious TEAEs were generally similar between treatment arms. A confirmatory phase 3 randomized, double-blind, placebo-controlled clinical trial of birtamimab in patients with Mayo stage IV AL amyloidosis (AFFIRM-AL; NCT04973137) is currently enrolling. The VITAL trial was registered at www.clinicaltrials.gov as #NCT02312206.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisAmyloidosisHumansStandard of CareAntibodies, Monoclonal, HumanizedDouble-Blind MethodTreatment Outcome

Substanzen

birtamimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Abramson Cancer Center, The Hospital of the University of Pennsylvania, Philadelphia, PA.
  • Divison of Hematology and Oncology, Tufts Medical Center, Boston, MA.
  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.

ORCID-Profile: Morie A Gertz, Adam D Cohen, Raymond L Comenzo, Efstathios Kastritis, Heather J Landau, Michaela Liedtke, Vaishali Sanchorawala, Giovanni Palladini, Giampaolo Merlini

Förderung

  • NCI NIH HHS

Zitieren

APA

Gertz, M. A., Cohen, A. D., Comenzo, R. L., Kastritis, E., Landau, H. J., Libby, E. N., Liedtke, M., Sanchorawala, V., Schönland, S., Wechalekar, A., Zonder, J. A., Palladini, G., Walling, J., Guthrie, S., Nie, C., Karp, C., Jin, Y., Kinney, G. G., & Merlini, G. (2023). Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood, 142(14), 1208-1218. https://doi.org/10.1182/blood.2022019406

Vancouver

Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, et al. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. 2023;142(14):1208-1218. doi:10.1182/blood.2022019406

BibTeX
@article{Gertz2023,
  author = {Gertz, Morie A and Cohen, Adam D and Comenzo, Raymond L and Kastritis, Efstathios and Landau, Heather J and Libby, Edward N and Liedtke, Michaela and Sanchorawala, Vaishali and Schönland, Stefan and Wechalekar, Ashutosh and Zonder, Jeffrey A and Palladini, Giovanni and Walling, Jackie and Guthrie, Spencer and Nie, Christie and Karp, Carol and Jin, Yuying and Kinney, Gene G and Merlini, Giampaolo},
  title = {Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial},
  journal = {Blood},
  year = {2023},
  volume = {142},
  number = {14},
  pages = {1208--1218},
  doi = {10.1182/blood.2022019406}
}
Kostenlos starten →